CytoDel Overview
- Year Founded
-
2012

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$295K
- Investors
-
4
CytoDel General Information
Description
Operator of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company's platform manipulates the BoNT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.
Contact Information
Website
www.cytodel.comCorporate Office
- 423 West 127th Street
- New York, NY 10027
- United States
Corporate Office
- 423 West 127th Street
- New York, NY 10027
- United States
CytoDel Timeline
CytoDel Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Grant | 01-Jan-2023 | $295K | Completed | Generating Revenue | ||
6. Grant | 01-Mar-2022 | Completed | Generating Revenue | |||
5. Accelerator/Incubator | Completed | Generating Revenue | ||||
4. Later Stage VC (Series A) | 16-Jan-2018 | Completed | Generating Revenue | |||
3. Grant | 01-Jul-2017 | Completed | Generating Revenue | |||
2. Grant | 01-Jan-2014 | $224K | Completed | Generating Revenue | ||
1. Accelerator/Incubator | 13-Dec-2013 | Completed | Generating Revenue |
CytoDel Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A-1 | ||||||||
Series A-2 |
CytoDel Comparisons
Industry
Financing
Details
CytoDel Competitors (5)
One of CytoDel’s 5 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
Biogen | Formerly VC-backed | Cambridge, MA | ||||
Eli Lilly | Corporation | Indianapolis, IN | ||||
AbbVie | Corporation | North Chicago, IL | ||||
Merz Pharma | Corporation | Frankfurt, Germany |
CytoDel Patents
CytoDel Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220333091-A1 | Recombinant botulinum neurotoxin with improved safety margin and reduced immunogenicity | Pending | 30-Sep-2019 |
CytoDel Signals
CytoDel Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Kairos Ventures | Venture Capital | Minority | ||
NYU Entrepreneurial Institute | Accelerator/Incubator | Minority | ||
National Institutes of Health | Government | |||
U.S. Department of Health and Human Services | Government |
CytoDel FAQs
-
When was CytoDel founded?
CytoDel was founded in 2012.
-
Where is CytoDel headquartered?
CytoDel is headquartered in New York, NY.
-
What is the size of CytoDel?
CytoDel has 5 total employees.
-
What industry is CytoDel in?
CytoDel’s primary industry is Drug Discovery.
-
Is CytoDel a private or public company?
CytoDel is a Private company.
-
What is CytoDel’s current revenue?
The current revenue for CytoDel is
. -
How much funding has CytoDel raised over time?
CytoDel has raised $3.9M.
-
Who are CytoDel’s investors?
Kairos Ventures, NYU Entrepreneurial Institute, National Institutes of Health, and U.S. Department of Health and Human Services have invested in CytoDel.
-
Who are CytoDel’s competitors?
Amgen, Biogen, Eli Lilly, AbbVie, and Merz Pharma are competitors of CytoDel.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »